Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
21
Frequently Asked Questions
What is Market Cap of Unicycive Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Unicycive Therapeutics Inc market cap is $175.91M.
What is the 52-week high for Unicycive Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Unicycive Therapeutics Inc 52 week high is $11.00 as of April 16, 2026.
What is the 52-week low for Unicycive Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Unicycive Therapeutics Inc 52 week low is $3.71 as of April 16, 2026.
What is Unicycive Therapeutics Inc stock price today?
Unicycive Therapeutics Inc stock price today is $6.90.
What was Unicycive Therapeutics Inc stock price yesterday?
Unicycive Therapeutics Inc stock price yesterday was $6.97.
What is the PE ratio of Unicycive Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Unicycive Therapeutics Inc's P/E ratio is -3.45.
What is the Price-to-Book ratio of Unicycive Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Unicycive Therapeutics Inc P/B ratio is 5.1044.
What is the 50-day moving average of Unicycive Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Unicycive Therapeutics Inc 50-day moving average is $6.67.
How many employees does Unicycive Therapeutics Inc have?